text stringlengths 0 5.79k |
|---|
#### IDH Mutations |
Somatic mutations affecting the Krebs cycle enzyme IDH1—predominantly at the R132 residue—were first identified in 12% of glioblastoma samples in 2008 and are now recognized as early, lineage‐defining events in diffuse gliomagenesis, occurring more commonly in lower grade gliomas [25, 26, 27]. These mutations confer ne... |
By definition, IDH1/2 mutations are present in IDH‐mutant astrocytomas and oligodendrogliomas and are associated with substantially prolonged survival compared with IDH‐wildtype tumors [2, 35, 36, 37, 38, 39]. IDH status is indispensable for integrated classification and can aid in distinguishing diffuse astrocytoma fr... |
#### ATRX Mutations |
ATRX alterations occur in > 70% of Grades 2 and 3 IDH‐mutant astrocytomas [26, 40, 41, 42]. ATRX encodes a chromatin remodeling helicase involved in histone H3.3 deposition at telomeres; loss‐of‐function is closely linked to alternative lengthening of telomeres (ALT), enabling telomere maintenance independent of telome... |
#### TP53 Mutations |
TP53 inactivation—often via missense mutation with accompanying chromosomal loss—is present in most IDH‐mutant astrocytomas [10, 24, 26, 43]. Mutations frequently involve the DNA‐binding domain (Exons 5, 7, and 8), disrupting sequence‐specific binding and core tumor‐suppressor functions [24]. TP53 loss promotes genomic... |
Together, IDH mutation + ATRX loss + TP53 inactivation define the early astrocytoma lineage program, upon which later events accumulate to govern malignant transformation, treatment sensitivity, and clinical trajectory [2, 9, 10, 11, 12, 24, 25, 26, 27, 35, 40, 41, 42, 43, 44]. |
### Historical Evolution and the WHO Integrated Framework |
Glioma classification has evolved from morphologic schemes to the modern WHO Classification, most recently updated in 2021 [1, 2, 8, 45, 46, 47, 48, 49]. Since 2016, diffuse gliomas have been classified using an integrated approach that combines histopathology with molecular parameters—centrally, IDH mutation status—in... |
This integrated framework is not merely taxonomic: it aligns diagnosis with biology, prognosis, and increasingly, therapy selection. |
### IDH Mutations and Diagnostic Work‐Up |
IDH1/2 mutations define the majority of WHO Grades 2 and 3 diffuse gliomas and confer improved prognosis [3, 27, 58]. Immunohistochemistry (IHC) for IDH1 R132H is the standard first‐line test [59, 60, 61]. However, 10%–20% of cases harbor noncanonical IDH mutations detectable only by sequencing, particularly in younger... |
If IHC is negative, sequencing of IDH1/2 is recommended for Grades 2 and 3 tumors and for Grade 4 tumors in patients < 55 years [1, 2, 3, 27, 58]. In IDH‐wildtype cases, further molecular work‐up (e.g., H3 K27M/G34 alterations, EGFR amplification, TERT promoter mutation) may be required to establish specific integrated... |
#### IDH1 vs. IDH2: Shared Biology, Distinct Clinical Context |
Although IDH1 and IDH2 mutations converge biologically through 2‐HG production, they are not fully interchangeable in clinical communication [1, 2, 3, 27, 58]. In diffuse gliomas, IDH1 mutations are substantially more common and are classically enriched at R132 (with R132H as the predominant hotspot), whereas IDH2 muta... |
#### 2‐HG–Driven Epigenetic Reprogramming and Downstream Oncogenic Pathways |
IDH1/2 hotspot mutations endow the enzyme with neomorphic activity that converts α‐ketoglutarate to R(–)‐2‐hydroxyglutarate (2‐HG), creating a sustained oncometabolite state that is tightly coupled to epigenetic remodeling [28, 29, 30, 31]. Mechanistically, 2‐HG perturbs the activity of α‐ketoglutarate–dependent dioxyg... |
Beyond global methylation shifts, IDH‐mutant gliomas exhibit higher order chromatin and regulatory architecture changes that can directly activate growth pathways [32]. In particular, insulator dysfunction and altered enhancer–promoter communication have been linked to aberrant oncogene activation, including PDGFRA, re... |
### Histopathologic Features and Grading Criteria |
Despite advances in molecular diagnostics, light microscopy remains the foundation of initial classification, and historical grading was anchored in anaplasia—mitotic activity defining Grade 3 and microvascular proliferation and/or necrosis defining Grade 4—within the context of classic astrocytic versus oligodendrogli... |
### Integrated Grading (CNS WHO Grades 2–4) |
Astrocytoma, IDH‐mutant is a single molecular entity stratified into three grades using integrated histologic and molecular criteria [1, 2]. |
#### Astrocytoma, IDH‐Mutant, CNS WHO Grade 2 |
Diffusely infiltrative tumors with nuclear atypia but lacking significant mitotic activity, necrosis, or microvascular proliferation. They typically affect younger adults, with median survival approaching ∼11 years in contemporary cohorts [3]. |
#### Astrocytoma, IDH‐Mutant, CNS WHO Grade 3 |
Characterized by increased cellularity and mitotic activity but lacking necrosis and microvascular proliferation [1, 2, 55]. Even within this category, outcomes remain variable, emphasizing that grade is necessary but not sufficient for individualized prognostication [2, 3, 6, 55]. |
#### Astrocytoma, IDH‐Mutant, CNS WHO Grade 4 |
Defined either by classic histologic features of glioblastoma (necrosis and/or microvascular proliferation) or by CDKN2A/B homozygous deletion [2, 3, 55, 66, 67]. Although IDH‐mutant Grade 4 tumors often occur in younger adults and may have better outcomes than IDH‐wildtype glioblastoma, they remain clinically aggressi... |
These integrated criteria provide the diagnostic foundation for risk stratification models that incorporate clinical status and imaging‐derived markers to delineate prognostic subgroups across the spectrum of IDH‐mutant astrocytomas. |
## Risk Stratification in IDH‐Mutant Astrocytomas |
IDH‐mutant astrocytomas span a wide clinical continuum—from indolent tumors compatible with decades‐long survival to aggressive CNS WHO Grade 4 disease with early malignant transformation. Risk stratification in this setting is ultimately a decision tool, designed to answer three practical questions: ① how aggressive i... |
Figure 2 summarizes a practical four‐domain model—clinical factors, histopathology, molecular biomarkers, and imaging/radiomics—that converges into an integrated risk score to guide treatment intensity, surveillance cadence, and trial stratification in IDH‐mutant astrocytomas. |
### Clinical Prognostic Factors: The “Patient and Presentation” Layer |
Several clinical factors established in pre‐molecular LGG cohorts remain directionally informative in IDH‐mutant astrocytomas—age, baseline performance status, tumor size/location, neurologic deficit, and extent of resection (EOR). In the EORTC LGG analysis, age ≥ 40 years, tumor diameter ≥ 6 cm, midline crossing, astr... |
Within IDH‐defined cohorts, younger age, higher KPS, seizure‐only presentation, non‐eloquent location, and more extensive resection correlate with longer PFS and OS, although the prognostic separation attributed to traditional “low‐ versus high‐grade” distinctions is attenuated once IDH status is incorporated [3, 5]. A... |
### Histopathological Grading: Necessary, but Not Sufficient |
Histopathological grading remains clinically relevant but imperfect in IDH‐mutant astrocytomas. The WHO 2021 framework recognizes CNS WHO Grades 2–4 for astrocytoma, IDH‐mutant using integrated histologic and molecular criteria, including mitotic activity, microvascular proliferation, necrosis, and CDKN2A/B homozygous ... |
### Molecular Biomarkers: The “Biology That Overrides Grade” Layer |
Beyond the defining IDH1/2 mutation, several biomarkers have reproducible prognostic implications and increasingly shape integrated risk assignment. |
#### CDKN2A/B Homozygous Deletion |
Across cohorts and an individual‐patient meta‐analysis, CDKN2A/B homozygous deletion is among the strongest adverse markers, associated with markedly reduced OS and PFS across grades [4, 71]. This evidence underpins the WHO 2021 designation of CNS WHO Grade 4 for tumors harboring CDKN2A/B homozygous deletion even in th... |
#### Global DNA Methylation |
Weller et al. reported that lower global DNA methylation (e.g., LINE‐1 methylation) associates strongly with Grade 4 biology and poor outcomes; combining LINE‐1 methylation with CDKN2A copy number identifies prognostic subgroups beyond histologic grade alone [71]. |
#### TP53 and ATRX Alterations |
TP53 mutation and ATRX loss support astrocytic lineage and help distinguish IDH‐mutant astrocytoma from oligodendroglioma. While typically less prognostically dominant than CDKN2A/B status, these alterations contribute to multivariable models and confirm diagnostic context [3, 5]. |
#### IDH Mutation Type and Other Co‐Alterations |
Noncanonical IDH1 and IDH2 mutations are uncommon and have been associated with slightly more favorable outcomes than canonical IDH1 R132H in some series, though findings are not fully consistent [71, 72]. Additional alterations (e.g., MGMT promoter methylation, TERT promoter mutation, copy‐number changes) may refine r... |
### Integrated Risk Scores and Clinical Decision Frameworks: Making the Model Actionable |
Recent efforts increasingly emphasize IDH‐mutant–specific multidimensional models. Re‐analyses suggest that once IDH mutation and CDKN2A/B status are incorporated, histologic grade regains prognostic relevance primarily within molecularly defined categories rather than across the entire population [3, 5]. In the Weller... |
In practice, integrated assessment is used to guide decisions such as early versus deferred RT/chemotherapy in Grade 2, the intensity of multimodality therapy in Grades 3 and 4, and eligibility/stratification for trials of IDH inhibitors and other targeted approaches. Prospective validation—particularly in the post‐vor... |
### Imaging and Radiomics: Quantifying Burden and Biological Behavior |
Imaging provides structural and functional surrogates of tumor biology and is increasingly incorporated into risk stratification. In IDH‐mutant astrocytomas, conventional MRI markers reflecting aggressiveness or higher active burden include: Contrast enhancement,substantial postoperative residual disease / higher resid... |
Across cohorts, enhancement and higher residual tumor volume correlate with shorter PFS and OS and are therefore used as pragmatic imaging risk markers alongside histomolecular assessment [71, 73]. |
A widely cited radiogenomic clue is the T2–FLAIR mismatch sign, defined by predominantly homogeneous T2 hyperintensity with relative FLAIR hypointensity except for a hyperintense peripheral rim. Multiple studies indicate high specificity for IDH‐mutant, 1p/19q–non‐codeleted astrocytoma, although sensitivity is limited ... |
Beyond qualitative signs, radiomics and machine‐learning approaches extract quantitative MRI features (shape, texture, intensity, spatial heterogeneity) to predict molecular subtype, grade, and outcome. Systematic analyses suggest that radiomics models using multimodal MRI can predict IDH status and 1p/19q codeletion w... |
## Standard Therapies for IDH‐Mutant Astrocytomas |
### Surgical Management |
Maximal safe resection is the cornerstone of initial management for suspected diffuse gliomas across grades, including IDH‐mutant astrocytomas. Surgery is both diagnostic and therapeutic, providing tissue for integrated histomolecular classification while reducing tumor burden and alleviating mass effect. The extent of... |
#### Surgical Planning |
Preoperative planning integrates standard structural MRI with advanced functional and connectivity imaging. Functional MRI and diffusion tensor imaging help define the relationship between tumor, eloquent cortex, and major white matter tracts, thereby informing strategies to maximize resection while preserving neurolog... |
#### Timing of Surgery |
Surgery is generally indicated at presentation for large, symptomatic, or radiologically aggressive tumors, including lesions with contrast enhancement, necrosis, or substantial edema. For small, nonenhancing, minimally symptomatic lesions suggestive of CNS WHO Grade 2 IDH‐mutant astrocytoma, contemporary consensus lik... |
#### Extent of Resection |
Multiple retrospective and prospective series support an association between greater extent of resection and improved progression‐free and overall survival in diffuse gliomas, including IDH‐mutant astrocytomas [81, 85, 86, 87, 88, 89, 90]. For resectable tumors, complete or near‐complete resection is consistently super... |
### Selection of Postoperative Therapy |
Surgery alone is rarely curative for diffuse gliomas, including IDH‐mutant astrocytomas, and most patients ultimately require adjuvant radiotherapy (RT), chemotherapy, IDH‐targeted agents, or combinations thereof [91]. Postoperative management should be individualized and risk‐adapted based on tumor grade, imaging feat... |
#### Grade 2 IDH‐Mutant Astrocytomas |
##### Postoperative Pathways (Outside Clinical Trials) |
Postoperative management for IDH‐mutant CNS WHO Grade 2 astrocytomas generally follows one of three pathways: ① active surveillance, ② radiotherapy (RT) plus chemotherapy, or ③ IDH‐targeted therapy in selected patients when the goal is to defer chemoradiation‐related neurotoxicity [96]. Vorasidenib, an oral dual IDH1/2... |
##### Risk Stratification (Pragmatic Triggers for Early Chemoradiation) |
Risk stratification is increasingly anchored in clinical urgency and imaging biology, rather than age or grade alone [96, 97]. Features commonly treated as “higher risk / higher urgency” include: persistent or progressive neurologic symptoms,contrast enhancement on MRI,substantial postoperative residual disease, andrap... |
Patients with these features are typically directed toward earlier RT plus chemotherapy, whereas those without them—especially after maximal resection—may be managed with surveillance and/or IDH inhibition to defer cytotoxic therapy and preserve neurocognitive function and quality of life [96, 97]. |
##### After Gross Total Resection: Surveillance as Default, Individualized Exceptions |
After gross total resection, near‐term progression risk is often low and watchful waiting is commonly preferred over immediate RT/chemotherapy to limit cumulative toxicity [99]. Because INDIGO required nonenhancing measurable disease, patients without measurable residual tumor were not eligible; therefore, routine upfr... |
##### Natural History After Complete Resection (Succinct Evidence Context) |
Long‐term outcome data after complete resection largely derive from pre‐molecular series. In a prospective cohort of 111 low‐grade glioma patients with radiographically complete resection, OS at 2 and 5 years was 99% and 93%, and ∼50% remained progression‐free at 5 years; larger tumor size (≥ 4 cm), astrocytic/oligoast... |
##### Surveillance Schedule (Typical Practice) |
Postoperative surveillance commonly uses contrast‐enhanced MRI every 3–4 months in the first postoperative years, extending to ∼6 monthly intervals after 1 and 2 years of stability; because most recurrences arise at or near the resection cavity margin, any new neurologic deficit, new nodular/ring‐like enhancement, or s... |
##### Management at Progression After Initial Surgery ± Observation |
Management at progression is individualized based on tumor volume/location, resectability, imaging features (including enhancement), histopathology at recurrence, prior therapies, and patient priorities [101, 102]. Common components include: Re‐resection (preferred when feasible)When radiographically and functionally r... |
##### Subtotal Resection Without Uncontrolled Symptoms: The INDIGO‐Defined Niche |
In patients with residual disease after subtotal resection but without uncontrolled symptoms—particularly with nonenhancing measurable disease—vorausidenib is increasingly used to defer RT and alkylating chemotherapy [98, 103, 104, 105]. The Phase 3 INDIGO trial randomized 331 patients ≥ 12 years with residual or recur... |
Because INDIGO excluded enhancing tumors, current practice generally reserves vorasidenib for nonenhancing lesions in which the risk of histologic undergrading is considered low (e.g., after generous sampling) [98, 103, 104, 105]. There is no consensus residual‐size threshold; expert reviews emphasize individualized de... |
##### Uncontrolled Symptoms or Progression on Vorasidenib: Escalation to RT Plus Chemotherapy |
If patients develop uncontrolled symptoms or radiologic progression on vorasidenib, RT plus chemotherapy becomes the preferred strategy unless repeat surgery is feasible and expected to provide meaningful benefit [107]. Rationale for RT plus chemotherapyRandomized trials in diffuse low‐grade gliomas support RT combined... |
Figure 3 outlines a pragmatic, risk‐triggered postoperative pathway for Grade 2 IDH‐mutant astrocytomas, linking extent of resection (GTR vs. STR/biopsy), high‐risk imaging/clinical features, and progression status to surveillance, IDH inhibition, re‐resection, or escalation to RT plus chemotherapy within a shared deci... |
#### Grade 3 IDH‐Mutant Astrocytomas |
##### Selection of Therapy |
For newly diagnosed IDH‐mutant CNS WHO Grade 3 astrocytomas, standard postoperative management typically consists of radiotherapy (RT) followed by adjuvant chemotherapy (temozolomide or PCV), reflecting evidence from randomized trials in 1p/19q–non‐codeleted anaplastic gliomas that demonstrated superior survival with c... |
Temozolomide is generally preferred in contemporary practice because of its favorable toxicity profile, ease of administration, and evidence base supporting RT followed by adjuvant temozolomide in this population [108, 109]. At present, IDH inhibitors (e.g., vorasidenib) have no established role in Grade 3 tumors outsi... |
##### Supporting Evidence |
The EORTC 26053–22033 CATNON trial enrolled 751 adults with 1p/19q–non‐codeleted Grade 3 gliomas (including both IDH‐mutant and IDH‐wildtype tumors) and randomized patients to: RT alone,RT with concurrent temozolomide,RT with concurrent plus adjuvant temozolomide (12 cycles), orRT with adjuvant temozolomide alone [108]... |
At a median follow‐up of 56 months, adjuvant temozolomide significantly improved overall survival versus no adjuvant temozolomide (82 vs. 47 months; HR 0.64, 95% CI 0.52–0.79), with a pronounced benefit in IDH‐mutant tumors (117 vs. 78 months; HR 0.48, 95% CI 0.35–0.67); no benefit was observed in IDH‐wildtype tumors (... |
Earlier trials (EORTC 26951; RTOG 9402) in anaplastic oligodendroglioma/oligoastrocytoma populations showed survival benefit with RT plus PCV—most prominently in 1p/19q‐codeleted tumors—with only a nonsignificant trend in IDH‐mutant, non‐codeleted subsets [119, 120, 121]. Accordingly, temozolomide has largely supplante... |
Figure 4 summarizes an evidence‐based postoperative management pathway for CNS WHO Grades 3 and 4 IDH‐mutant astrocytomas, highlighting RT followed by adjuvant alkylating chemotherapy as the backbone for Grade 3 (CATNON: benefit from adjuvant, not concurrent, temozolomide; temozolomide generally favored over PCV), and ... |
#### Grade 4 IDH‐Mutant Astrocytomas |
Under the 2021 WHO classification, tumors previously termed “glioblastoma, IDH‐mutant” are classified as astrocytoma, IDH‐mutant, CNS WHO Grade 4 [2]. These tumors are biologically and prognostically distinct from IDH‐wildtype glioblastoma, tending to present at a younger age and more often exhibiting MGMT promoter met... |
In the absence of randomized trials specific to IDH‐mutant Grade 4 astrocytomas, postoperative management outside clinical trials generally follows one of two temozolomide‐based paradigms: RT followed by 12 cycles of adjuvant temozolomide, extrapolating from CATNON in IDH‐mutant Grade 3 disease; orRT with concurrent da... |
Both approaches are regarded as reasonable by expert panels, but are supported primarily by indirect evidence rather than trials restricted to IDH‐mutant Grade 4 disease [94]. In practice, selection is individualized: clinicians favoring concurrent chemoradiation cite historical glioblastoma datasets likely containing ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.